Business · 29/07/2026
FDA Classifies Phase-Changing Fiducial Marker for Radiation Therapy into Class II
The FDA has classified the phase-changing fiducial marker for radiation therapy into Class II, a move aimed at ensuring the device's safety and effectiveness while reducing regulatory burdens, ultimately enhancing patients' access to innovative devices.
Original source language: Federal Register — Health and Human ServicesOpen original release →